Be the voice of reason.

Her mind is made up, but uncertainty prevails.

It’s understandable that loved ones can be overwhelmed when diagnosed with breast cancer, but oftentimes that can lead to a hasty decision when it comes to treatment. Not all breast cancer is the same. Knowing the unique nature of an individual’s cancer helps determine the most effective course of treatment. Often, with early-stage invasive breast cancer, chemotherapy may not be beneficial.

The Oncotype DX breast cancer test is intended for women recently diagnosed with either early-stage invasive breast cancer or DCIS (non-invasive) breast cancer. It provides a personalized test score to help guide treatment decisions based on the activity of certain genes in the tumor tissue.

For early-stage invasive breast cancer, the Oncotype DX test is the only test that can help you determine if chemotherapy is the best treatment option or if a different approach might be more effective. To date, more than 170,000 breast cancer patients have changed their treatment decision based on the Oncotype DX test. Many of these women who received high Oncotype DX scores were able to choose chemotherapy as a potentially life-saving treatment, while the majority were able to effectively pursue hormonal therapy alone and avoid the unnecessary side effects of chemotherapy.

For DCIS, Oncotype DX can help determine the risk of cancer returning (recurrence), a key factor in deciding treatment after surgery.

The Oncotype DX breast cancer test is included in all major cancer treatment guidelines around the world, is widely covered by insurers, and is recognized as the new standard of care.

Help your loved one make the right breast cancer treatment decision with an Oncotype DX test score result. Making an informed decision is the first step to gaining peace of mind.